Psoriasis

  1. Jiménez Gómez, Natalia
  2. Ballester Martínez, María Asunción
  3. Pérez Gala, S.
  4. Gárate Ayastuy, Teresa
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2014

Título del ejemplar: Enfermedades de la piel (I): dermatosis infecciosas, descamativas, bullosas y sistémicas

Serie: 11

Número: 47

Páginas: 2764-2773

Tipo: Artículo

DOI: 10.1016/S0304-5412(14)70695-X DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

La psoriasis es una enfermedad crónica sistémica, con manifestaciones cutáneas y articulares de características inflamatorias. Sus lesiones cutáneas típicas consisten en placas eritematodescamativas bien delimitadas, localizadas en áreas de extensión. Se considera una enfermedad de base genética, sobre la que actúan distintos factores ambientales que pueden desencadenar las lesiones. El diagnóstico de la enfermedad es clínico, pudiendo apoyarse en la biopsia cutánea. La psoriasis leve/moderada puede manejarse con tratamiento tópico, incluyendo corticoides, derivados de la vitamina D o A, inhibidores de la calcineurina o combinaciones de los anteriores. En los casos más extensos, emplearemos tratamiento sistémico basado en la fototerapia, los fármacos clásicos (metotrexato, ciclosporina, retinoides) o los fármacos biológicos. En esta revisión, actualizaremos el manejo de dicha patología y repasaremos las principales enfermedades eritematodescamativas.

Referencias bibliográficas

  • K. Reich The concept of psoriasis as a systemic inflammation: implications for disease management J Eur Acad Dermatol Venereol, 26Suppl2 (2012), pp. 3-11
  • J.E. Gudjonsson, J.T. Elder Psoriasis: epidemiology Clin Dermatol, 252 (6) (2007), pp. 535-546
  • N. Weigle, S. McBane Psoriasis Am Fam Physician, 87 (9) (2013), pp. 626-633
  • K.C. Duffin, V. Chandran, D. Gladman, G.G. Krueger, J.T. Elder, P. Rahman Genetics of psoriasis and psoriatic arthritis: update and future direction (GRAPPA 2007) J Rheumatol, 35 (7) (2008), pp. 1449-1453
  • H. Valdimarsson The genetic basis of psoriasis Clin Dermatol, 25 (6) (2007), pp. 563-567
  • K. Ghoreschi, C. Weigert, M. Röcken Immunopathogenesis and role of T cells in psoriasis Clin Dermatol, 25 (6) (2007), pp. 574-580
  • L. Fry, B.S. Baker Triggering psoriasis: the role of infections and medications Clin Dermatol, 25 (6) (2007), pp. 606-615
  • A.W. Armstrong, E.J. Armstrong, E.N. Fuller, M.E. Sockolov, S.V. Voyles Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms Br J Dermatol, 165 (6) (2011), pp. 1162-1168
  • W. Carey, S. Glazer, A.B. Gottlieb, M. Lebwohl, C. Leonardi, A. Menter Relapse, rebound, and psoriasis adverse events: an advisory group report J Am Acad Dermatol, 54 (4Suppl1) (2006), pp. S171-S181
  • L. Naldi, D. Gambini The clinical spectrum of psoriasis Clin Dermatol, 25 (6) (2007), pp. 510-518
  • M.M. Roth Pregnancy dermatoses: diagnosis, management and controversies Am J Clin Dermatol, 12 (1) (2011), pp. 25-41
  • E. Daudén, S. Castañeda, C. Suárez, J. García-Campayo, A.J. Blasco, M.D. Aguilar Abordaje integral de la comorbilidad del paciente con psoriasis Actas Dermosifiliogr, 103 (Suppl1) (2012), pp. 1-64
  • H. Yeung, J. Takeshita, N.N. Mehta, S.E. Kimmel, A. Ogdie, D.J. Margolis Psoriasis severity and the prevalence of major medical comorbidity: a population based study JAMA Dermatol, 149 (10) (2013), pp. 1173-1179
  • A. Pickert Concise review of lichen planus and lichenoid dermatoses Cutis, 90 (3) (2012), pp. E1-E3
  • A.L. Sampaio, A.C. Mameria, T.J. Vargas Seborrheic dermatitis An Bras Dermatol, 86 (6) (2011), pp. 1061-1071
  • F. Drago, F. Broccolo, A. Rebora Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology J Am Acad Dermatol, 61 (2) (2009), pp. 303-318
  • M. Leger, T. Newlove, M. Robinson Pityriasis rubra pilaris Dermatol Online J, 18 (12) (2012), p. 14
  • J.M. Carrascosa, F. Vanaclocha, L. Borrego, E. Fernández López, A. Fuertes, L. Rodríguez Fernández Freire Revisión actualizada del tratamiento tópico de la psoriasis Actas Dermosifiliogr, 100 (2009), pp. 190-200
  • B.B. Davidovici, N. Sattar, J. Prinz, L. Puig, P. Emery, J.N. Barker Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and comorbid conditions J Invest Dermatol, 130 (7) (2010), pp. 1785-1796
  • K.H. Basavaraj, N.M. Ashok, R. Rashmi, T.K. Praveen The role of drugs in the induction and/or exacerbation of psoriasis Int J Dermatol, 49 (12) (2010), pp. 1351-1361
  • J. Mason, A.R. Mason, M.J. Cork Topical preparations for the treatment of psoriasis: a systematic review Br J Dermatol, 146 (2002), pp. 351-364
  • R. García Delgado, E. Escario Travesedo, A. Sánchez Romero Uso racional de la medicación tópica en dermatología Med Cutan Iber Lat Am, 32 (2004), pp. 39-44
  • D.M. Ashcroft, A.L. Po, H.C. Williams, C.E. Griffiths Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis BMJ, 320 (2000), pp. 963-997
  • J.M. Camarasa, J.P. Ortonne, L. Dubertret Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy J Dermatolog Treat, 14 (2003), pp. 8-13
  • M. Sánchez Regaña Is there a useful topical treatment for nail psoriasis? Piel (Barc), 28 (7) (2013), pp. 381-383
  • J.Y. Koo, D. Martin Investigator masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis Int J Dermatol, 40 (2001), pp. 210-212
  • J.M. Carrascosa Fototerapia fotoquimioterapia Actas Dermosifiliogr, 95 (5) (2004), pp. 259-284
  • S.H. Ibbotson, D. Bilsland, N.H. Cox, R.S. Dawe, B. Diffey, C. Edwards An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report Br J Dermatol, 151 (2004), pp. 283-297
  • J.M. Carrascosa, J. Gardeazábal, A. Pérez Ferriols, A. Alomar, P. Manrique, M. Jones Caballero Documento de consenso sobre fototerapia: terapias PUVA y UVB de banda estrecha Actas Dermosifiliogr, 96 (10) (2005), pp. 635-658
  • W. Lapolla, B.A. Yentzer, J. Bagel, C.R. Halvorson, S.R. Feldman A review of phototherapy protocols for psoriasis treatment J Am Acad Dermatol, 5 (2011), pp. 936-949
  • H. Montaudié, E. Sbidian, C. Paul, A. Maza, A. Gallini, S. Aractingi Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity J Eur Acad Dermatol Venereol, 25 (Suppl2) (2011), pp. 12-18
  • A. Maza, H. Montaudié, E. Sbidian, A. Gallini, S. Aractingi, F. Aubin Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in nonplaque psoriasis J Eur Acad Dermatol Venereol, 25 (Suppl2) (2011), pp. 19-27
  • E. Sbidian, A. Maza, H. Montaudié, A. Gallini, S. Aractingi, F. Aubin Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review J Eur Acad Dermatol Venereol, 25 (Suppl2) (2011), pp. 28-33
  • A. Boada García, M. Ribera Pibernat Actualización del uso del acitretino en la psoriasis Piel, 22 (9) (2007), pp. 459-464
  • C. Paul, A. Gallini, A. Maza, H. Montaudié, E. Sbidian, S. Aractingi Evidence based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists J Eur Acad Dermatol Venereol, 25 (Suppl2) (2011), pp. 2-11
  • L. Puig, J.M. Carrascosa, G. Carretero, P. de la Cueva, F.R. Lafuente Urrez, I. Belinchón Spanish Evidence Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013 Part 1: On Efficacy and Choice of Treatment Actas Dermosifiliogr, 104 (8) (2013), pp. 694-709
  • C. Leonardi, B. Strober, A.B. Gottlieb, B.E. Elewski, J.P. Ortonne, P. van de Kerkhof Long term safety and efficacy of etanercept in patients with psoriasis: An open label study J Drugs Dermatol, 9 (2010), pp. 928-937
  • K.B. Gordon, R.G. Langley, C. Leonardi, D. Toth, M.A. Menter, S. Kang Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double blind, randomized controlled trial and open label extension study J Am Acad Dermatol, 55 (4) (2006), pp. 598-606
  • I.B. McInnes, A. Kavanaugh, A.B. Gottlieb, L. Puig, P. Rahman, C. Ritchlin PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double blind, placebo controlled PSUMMIT 1 trial Lancet, 382 (9894) (2013), pp. 780-789
  • K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52 week results from a randomised, double-blind, placebo controlled trial (PHOENIX 2) Lancet, 371 (9625) (2008), pp. 1675-1684
Fuente de los datos: Dialnet